185 related articles for article (PubMed ID: 24303016)
1. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).
Alaggio R; Turrini R; Boldrin D; Merlo A; Gambini C; Ferrari A; Dall'igna P; Coffin CM; Martines A; Bonaldi L; De Salvo GL; Zanovello P; Rosato A
PLoS One; 2013; 8(11):e80456. PubMed ID: 24303016
[TBL] [Abstract][Full Text] [Related]
2. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
Kresse SH; Skårn M; Ohnstad HO; Namløs HM; Bjerkehagen B; Myklebost O; Meza-Zepeda LA
Mol Cancer; 2008 Jun; 7():48. PubMed ID: 18522746
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor.
Krawczyk MA; Karpinsky G; Izycka-Swieszewska E; Gabrych A; Kunc M; Fatyga A; Garstka M; Styczewska M; Sokolewicz EM; Szlagatys-Sidorkiewicz A; Kazanowska B; Bien E
Cancer Biomark; 2019; 24(3):351-361. PubMed ID: 30883338
[TBL] [Abstract][Full Text] [Related]
4. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
[TBL] [Abstract][Full Text] [Related]
5. Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.
Karpinsky G; Krawczyk MA; Izycka-Swieszewska E; Fatyga A; Budka A; Balwierz W; Sobol G; Zalewska-Szewczyk B; Rychlowska-Pruszynska M; Klepacka T; Dembowska-Baginska B; Kazanowska B; Gabrych A; Bien E
J Cancer Res Clin Oncol; 2018 Mar; 144(3):519-529. PubMed ID: 29332262
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours.
Storlazzi CT; Brekke HR; Mandahl N; Brosjö O; Smeland S; Lothe RA; Mertens F
J Pathol; 2006 Aug; 209(4):492-500. PubMed ID: 16721726
[TBL] [Abstract][Full Text] [Related]
7. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
Zou C; Smith KD; Liu J; Lahat G; Myers S; Wang WL; Zhang W; McCutcheon IE; Slopis JM; Lazar AJ; Pollock RE; Lev D
Ann Surg; 2009 Jun; 249(6):1014-22. PubMed ID: 19474676
[TBL] [Abstract][Full Text] [Related]
8. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours.
Karube K; Nabeshima K; Ishiguro M; Harada M; Iwasaki H
J Clin Pathol; 2006 Feb; 59(2):160-5. PubMed ID: 16443732
[TBL] [Abstract][Full Text] [Related]
9. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
10. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST.
Miao R; Wang H; Jacobson A; Lietz AP; Choy E; Raskin KA; Schwab JH; Deshpande V; Nielsen GP; DeLaney TF; Cote GM; Hornicek FJ; Chen YE
Radiother Oncol; 2019 Aug; 137():61-70. PubMed ID: 31078939
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
12. Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection.
Kolberg M; Høland M; Lind GE; Ågesen TH; Skotheim RI; Hall KS; Mandahl N; Smeland S; Mertens F; Davidson B; Lothe RA
Mol Oncol; 2015 Jun; 9(6):1129-39. PubMed ID: 25769404
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
14. Malignant peripheral nerve sheath tumors (MPNST): a SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population.
Bates JE; Peterson CR; Dhakal S; Giampoli EJ; Constine LS
Pediatr Blood Cancer; 2014 Nov; 61(11):1955-60. PubMed ID: 25130403
[TBL] [Abstract][Full Text] [Related]
15. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Holtkamp N; Atallah I; Okuducu AF; Mucha J; Hartmann C; Mautner VF; Friedrich RE; Mawrin C; von Deimling A
Neoplasia; 2007 Aug; 9(8):671-7. PubMed ID: 17786186
[TBL] [Abstract][Full Text] [Related]
16. Malignant peripheral nerve sheath tumors in children, adolescents, and young adults: Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry.
Meister MT; Scheer M; Hallmen E; Stegmaier S; Vokuhl C; von Kalle T; Fuchs J; Münter M; Niggli F; Ladenstein R; Kazanowska B; Ljungman G; Bielack S; Koscielniak E; Klingebiel T;
J Surg Oncol; 2020 Dec; 122(7):1337-1347. PubMed ID: 32812260
[TBL] [Abstract][Full Text] [Related]
17. Management of childhood malignant peripheral nerve sheath tumor.
Ferrari A; Bisogno G; Carli M
Paediatr Drugs; 2007; 9(4):239-48. PubMed ID: 17705563
[TBL] [Abstract][Full Text] [Related]
18. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors.
Ikuta K; Urakawa H; Kozawa E; Arai E; Zhuo L; Futamura N; Hamada S; Kimata K; Ishiguro N; Nishida Y
Clin Exp Metastasis; 2014 Aug; 31(6):715-25. PubMed ID: 24957185
[TBL] [Abstract][Full Text] [Related]
20. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
Hassan A; Pestana RC; Parkes A
Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
